FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128693714> ?p ?o ?g. }

• W3128693714 endingPage "S187" @default.
• W3128693714 startingPage "S186" @default.
• W3128693714 abstract "INTRODUCTION The development of allogeneic CD19 chimeric antigen receptor (CAR) T cells from healthy donors is a significant focus in cell therapy and is anticipated to overcome the technical and logistical challenges associated with autologous CAR-T cells. Unlike gene-edited approaches, which require inactivation of the endogenous αβ T cell receptor to reduce the risk of Graft-versus-Host Disease (GvHD), allogeneic Epstein-Barr Virus (EBV)-targeted T cells represent a clinically-advanced treatment modality that, to-date, has demonstrated a favorable safety profile with limited risks of GvHD or cytokine release syndrome [Prockop et al. JCI, 2020; Prockop et al. Blood, 2019] . As an allogeneic CAR T cell platform, EBV T cells represent a unique composition that retains critical transducibility and function, and minimizes risks for GvHD and other host interactions, without requiring complex gene editing or other cell engineering approaches to facilitate use in the allogeneic setting. Recent clinical experience with allogeneic CD19 CAR-modified EBV T cells have further supported safe and effective clinical experience in the context of B cell malignancies [Curran KJ et al. TCT 2020]. Recent advances in next-generation stimulatory domains also represent potential for improvement on current CAR-T therapies. Specifically, a modified CD3ζ domain retaining signaling capacity in 1 of 3 immune-receptor-tyrosine-based-activation-motif (ITAM) regions (referred to as 1XX) is designed to extend functional persistence without compromising potency via calibration of antigen induced CAR signaling intensity to more physiologic levels [Feucht et al. Science Trans Med 2018]. Here, we describe the first preclinical evaluation of ATA3219, a next-generation allogeneic CD19 CAR T cell therapy, combining a non-edited allogeneic EBV T cell approach with a CAR signaling domain designed to improve upon the currently clinically validated CD19 targeted CAR therapies. METHODS and RESULTS We generated EBV T cells engineered with a CD19-targeted CAR containing a modified CD3ζ signaling domain, 1XX (CD19-1XX CAR+ EBV T cells). CD19-1XX CAR+ EBV T cells demonstrate high CAR expression, polyfunctionality, expansion and in vitro potency through HLA-independent killing of CD19+ targets. Furthermore, CD19-1XX CAR+ EBV T cells demonstrate highly potent antitumor activity in an established disseminated tumor model of acute lymphoblastic leukemia and is associated with long-term persistence of the product. No treatment-related toxicities were observed in this animal model. CONCLUSIONS This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrate, persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells, both in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation. Disclosures Pham: Atara Biotherapeutics: Current Employment, Current equity holder in publicly-traded company. Spindler: Atara Biotherapeutics: Current Employment, Current equity holder in publicly-traded company. Hwang: Atara Biotherapeutics: Current Employment, Current equity holder in publicly-traded company. Brito: Atara Biotherapeutics: Current Employment, Current equity holder in publicly-traded company. Bulliard: Atara Biotherapeutics: Current Employment, Current equity holder in publicly-traded company. Aftab: Atara Biotherapeutics: Current Employment, Current equity holder in publicly-traded company." @default.
• W3128693714 created "2021-02-15" @default.
• W3128693714 creator A5005105589 @default.
• W3128693714 creator A5012025508 @default.
• W3128693714 creator A5025110725 @default.
• W3128693714 creator A5051813475 @default.
• W3128693714 creator A5065049225 @default.
• W3128693714 creator A5087385557 @default.
• W3128693714 date "2021-03-01" @default.
• W3128693714 modified "2023-09-26" @default.
• W3128693714 title "ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing" @default.
• W3128693714 doi "https://doi.org/10.1016/s2666-6367(21)00229-3" @default.
• W3128693714 hasPublicationYear "2021" @default.
• W3128693714 type Work @default.
• W3128693714 sameAs 3128693714 @default.
• W3128693714 citedByCount "0" @default.
• W3128693714 crossrefType "journal-article" @default.
• W3128693714 hasAuthorship W3128693714A5005105589 @default.
• W3128693714 hasAuthorship W3128693714A5012025508 @default.
• W3128693714 hasAuthorship W3128693714A5025110725 @default.
• W3128693714 hasAuthorship W3128693714A5051813475 @default.
• W3128693714 hasAuthorship W3128693714A5065049225 @default.
• W3128693714 hasAuthorship W3128693714A5087385557 @default.
• W3128693714 hasBestOaLocation W31286937141 @default.
• W3128693714 hasConcept C104317684 @default.
• W3128693714 hasConcept C111599444 @default.
• W3128693714 hasConcept C117671659 @default.
• W3128693714 hasConcept C127413603 @default.
• W3128693714 hasConcept C141231307 @default.
• W3128693714 hasConcept C143998085 @default.
• W3128693714 hasConcept C144501496 @default.
• W3128693714 hasConcept C147483822 @default.
• W3128693714 hasConcept C203014093 @default.
• W3128693714 hasConcept C2778957590 @default.
• W3128693714 hasConcept C2982819384 @default.
• W3128693714 hasConcept C54355233 @default.
• W3128693714 hasConcept C71924100 @default.
• W3128693714 hasConcept C86803240 @default.
• W3128693714 hasConceptScore W3128693714C104317684 @default.
• W3128693714 hasConceptScore W3128693714C111599444 @default.
• W3128693714 hasConceptScore W3128693714C117671659 @default.
• W3128693714 hasConceptScore W3128693714C127413603 @default.
• W3128693714 hasConceptScore W3128693714C141231307 @default.
• W3128693714 hasConceptScore W3128693714C143998085 @default.
• W3128693714 hasConceptScore W3128693714C144501496 @default.
• W3128693714 hasConceptScore W3128693714C147483822 @default.
• W3128693714 hasConceptScore W3128693714C203014093 @default.
• W3128693714 hasConceptScore W3128693714C2778957590 @default.
• W3128693714 hasConceptScore W3128693714C2982819384 @default.
• W3128693714 hasConceptScore W3128693714C54355233 @default.
• W3128693714 hasConceptScore W3128693714C71924100 @default.
• W3128693714 hasConceptScore W3128693714C86803240 @default.
• W3128693714 hasIssue "3" @default.
• W3128693714 hasLocation W31286937141 @default.
• W3128693714 hasOpenAccess W3128693714 @default.
• W3128693714 hasPrimaryLocation W31286937141 @default.
• W3128693714 hasRelatedWork W2213064688 @default.
• W3128693714 hasRelatedWork W2412674143 @default.
• W3128693714 hasRelatedWork W2907243755 @default.
• W3128693714 hasRelatedWork W2943161966 @default.
• W3128693714 hasRelatedWork W3034349905 @default.
• W3128693714 hasRelatedWork W3105367689 @default.
• W3128693714 hasRelatedWork W3109143741 @default.
• W3128693714 hasRelatedWork W4207051488 @default.
• W3128693714 hasRelatedWork W4365811064 @default.
• W3128693714 hasRelatedWork W4366826326 @default.
• W3128693714 hasVolume "27" @default.
• W3128693714 isParatext "false" @default.
• W3128693714 isRetracted "false" @default.
• W3128693714 magId "3128693714" @default.
• W3128693714 workType "article" @default.